Skip Navigation

Philips Respironics issued a recall for some CPAP and BiLevel PAP devices and mechanical ventilators. Learn more.


COVID-19: We are vaccinating patients ages 12+. Learn more:

Vaccines | Testing | Patient Care | Visitor Guidelines | Coronavirus | Self-Checker | Email Alerts

Menu Search
Johns Hopkins Children’s Center

In This Section      


The Johns Hopkins Pediatric Diabetes Center has a growing clinical research program.

Our Pediatric Diabetes Researchers

Sheela Magge, M.D., M.S.C.E., is a clinician investigator dedicated to improving the lives of children with type 2 diabetes, obesity and insulin resistance, as well as the cardiovascular implications of these conditions. Magge is interested in how differences in body composition, whether due to race or a specific medical condition, can modify risk for cardiovascular disease and diabetes. She has performed patient-oriented research throughout her career, including clinical studies of dyslipidemia and cardiovascular disease in patients with pediatric prediabetes and type 2 diabetes, clinical trials of new oral medications to treat type 2 diabetes in children, studies of diabetes and cardiovascular risk in adolescents with Down syndrome, and work on the mechanisms behind differences in risk among people of different races, specifically South Asians, African Americans and white adolescents. Magge is also involved in a variety of projects aimed at preventing obesity and type 2 diabetes in children and adolescents.

Risa Wolf, M.D., is the principal investigator of a study implementing point-of-care diabetes retinopathy screening using artificial intelligence software in pediatric diabetes care, and she is the principal investigator for the Pediatric Diabetes Consortium site at Johns Hopkins. Wolf is also involved in the Diabetes Study of Linagliptin and Empagliflozin in Children and Adolescents, research regarding oral medications for treatment of children and adolescents with type 2 diabetes. She is also a co-investigator for Trialnet’s Pathway to Prevention study, enrolling family members of people with type 1 diabetes. Wolf is also investigating mechanisms of diabetes resolution in adults and adolescents undergoing bariatric weight loss surgery. 

Scott Blackman, M.D., Ph.D., is an associate professor of pediatrics in the Division of Pediatric Endocrinology and Diabetes, and an affiliate of the McKusick-Nathans Institute of Genetic Medicine. His research interests include identifying genetic variants responsible for endocrine abnormalities in cystic fibrosis (CF), including cystic fibrosis-related diabetes (CFRD), which is seen commonly in teenagers and adults with the disease. Blackman is one of five mentors in EnVision CF, a nationwide program with the goal of training academic physicians in CF endocrinology. He serves on the program planning committee of the North American Cystic Fibrosis Conference and the editorial board of the Journal of Cystic Fibrosis. He is also the site coordinator for the T1D Exchange.

Scott Blackman’s team identified five risk genes, aka genetic modifiers, of CFRD, including four genes associated with type 2 diabetes, which identify areas of overlapping pathophysiology for CFRD and type 2 diabetes. One modifier gene encodes a channel protein known to associate with the cystic fibrosis transmembrane conductance regulator (CFTR), suggesting that it could affect multiple aspects of CF disease. Multiple follow-up projects include:

  1. To better understand how genetic modifiers influence underlying metabolic abnormalities (such as insulin deficiency or insulin resistance), we are measuring profiles of multiple hormones during glucose tolerance testing in people with CF.
  2. We are conducting a follow-up genomewide association study to identify new CFRD risk genes.
  3. We are investigating how gene variants affect other metabolic problems in CF, such as poor weight gain (or obesity).
  4. We are analyzing the relationship between the CF-causing mutations in CFTR and the risk of diabetes, using data from the CFTR2 study of >90,000 people with CF.
  5. We are conducting other research projects that are aimed at understanding the relationship between CF-related liver disease and CFRD, and the effect of prediabetes (including impaired fasting glucose) on CF outcomes.

Explore the Children's Center

Find A Pediatric Specialist
Search our experts by specialty, disease, or condition
Health Information
Get the facts on diseases, conditions, tests and procedures